$1.02
0.00% yesterday
Nasdaq, Oct 03, 10:00 pm CET
ISIN
US70465T1079
Symbol
PDSB

PDS Biotechnology Corp. Stock price

$1.02
-0.28 21.54% 1M
-0.03 2.86% 6M
-0.61 37.42% YTD
-2.94 74.24% 1Y
-2.26 68.90% 3Y
-1.23 54.67% 5Y
-369.58 99.72% 10Y
-257.78 99.61% 20Y
Nasdaq, Closing price Fri, Oct 03 2025
+0.00 0.00%
ISIN
US70465T1079
Symbol
PDSB
Industry

Key metrics

Basic
Market capitalization
$48.0m
Enterprise Value
$34.6m
Net debt
positive
Cash
$31.9m
Shares outstanding
46.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
3.0
Financial Health
Equity Ratio
41.9%
Return on Equity
-197.9%
ROCE
-118.4%
ROIC
-
Debt/Equity
1.2
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-34.2m | $-41.4m
EBIT
$-34.3m | $-38.3m
Net Income
$-36.6m | $-39.2m
Free Cash Flow
$-34.4m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
13.7% | -14.2%
EBIT
13.7% | -5.4%
Net Income
10.0% | -4.1%
Free Cash Flow
0.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.8
FCF per Share
$-0.7
Short interest
3.8%
Employees
24
Rev per Employee
$0.0
Show more

Is PDS Biotechnology Corp. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

PDS Biotechnology Corp. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a PDS Biotechnology Corp. forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a PDS Biotechnology Corp. forecast:

Buy
89%
Hold
11%

Financial data from PDS Biotechnology Corp.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 13 13
11% 11%
-
- Research and Development Expense 21 21
15% 15%
-
-34 -34
14% 14%
-
- Depreciation and Amortization 0.06 0.06
0% 0%
-
EBIT (Operating Income) EBIT -34 -34
14% 14%
-
Net Profit -37 -37
10% 10%
-

In millions USD.

Don't miss a Thing! We will send you all news about PDS Biotechnology Corp. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PDS Biotechnology Corp. Stock News

Neutral
GlobeNewsWire
16 days ago
First combination therapy to report 29.5 months of Median Overall Survival (mOS); Standard of care Keytruda ® (pembrolizumab) alone (10.8 months) and Keytruda ® + chemotherapy (12.3 months) in patients with CPS 1-19*
Neutral
GlobeNewsWire
about one month ago
PRINCETON, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will participate in the 27th Annual H.C.
Neutral
GlobeNewsWire
about one month ago
Median Overall Survival (mOS) of 39.3 months in patients with CPS ≥ 1 – best published result with standard of care pembrolizumab or pembrolizumab + chemotherapy is 17.9 months*
More PDS Biotechnology Corp. News

Company Profile

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.

Head office United States
CEO Frank Bedu-Addo
Employees 24
Founded 2005
Website www.pdsbiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today